Fig. 3

Cytotoxicity of Anetumab Ravtansine as Measured with Cell Confluence. The effects of anetumab ravtansine at 0 nM, 10 nM, 50 nM, and 100 nM on mero-95 cell lines in the presence of no pretreatment (no pre-tx), 1% DMSO control, recombinant MSLN (rMSLN), marimastat (M), TMI-1 (T), and a combination of both protease inhibitors (M + T). At baseline, the combination M + T resulted in decreased confluence compared to rMSLN (p = 0.0003), M (p = 0.0028), T (p = 0.0252). At 10 nM of anetumab ravtansine, the addition of rMSLN resulted in higher confluence or less cytotoxicity compared to control DMSO (p = 0.0348), T (p = 0.0289), M + T (p = 0.0206) but not M (p = 0.0679). This trend continued at 50 nM. At 100 h nM, there were no significant differences between the groups. See Supplemental Table 2 and Fig. 1 for more detailed results. ARav = anetumab ravtansine. * p ≤ 0.05, ** p ≤ 0.01.